Elanco Animal Health (NYSE:ELAN) Updates FY25 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.80-$0.86 for the period, compared to the consensus earnings per share estimate of $0.89. The company issued revenue guidance of $4.445-$4.510 billion, compared to the consensus revenue estimate of $4.52 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Analyst Ratings Changes

ELAN has been the topic of several recent analyst reports. Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. Barclays lifted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. UBS Group initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Stock Down 5.4 %

Shares of ELAN traded down $0.60 during mid-day trading on Tuesday, hitting $10.51. 4,621,139 shares of the company’s stock were exchanged, compared to its average volume of 4,672,827. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The company has a market cap of $5.20 billion, a PE ratio of 26.28, a P/E/G ratio of 2.50 and a beta of 1.42. The company has a 50-day simple moving average of $11.78 and a 200 day simple moving average of $13.09.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the business posted $0.08 EPS. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.